logo

Acadia Pharmaceuticals Inc (ACAD)



Trade ACAD now with
  Date
  Headline
7/21/2021 5:11:12 PM New England Journal Of Medicine Publishes Results From Phase 3 Study Of Pimavanserin In Dementia-Related Psychosis
6/3/2021 9:11:07 AM Acadia Says NUPLAZID Efficacy Data From OLE Study Published In Parkinsonism And Related Disorders
4/5/2021 6:41:04 AM Acadia Receives CRL From FDA For SNDA For Pimavanserin For Treatment Of Hallucinations And Delusions Associated With DRP
8/31/2020 9:08:23 AM ACADIA Pharmaceuticals Appoints Gudarz Davar EVP And Head Of Research And Development
7/20/2020 4:05:55 PM ACADIA Says Phase 3 CLARITY Study On Pimavanserin Did Not Achieve Statistical Significance On Primary Endpoint
6/15/2020 9:10:32 AM ACADIA Submits SNDA For NUPLAZID For Treatment Of Hallucinations, Delusions Associated With Dementia-Related Psychosis
5/26/2020 9:12:07 AM ACADIA To Merge CLARITY-2, CLARITY-3 Phase 3 Studies showing Pimavanserin For Adjunctive Treatment Of MDD
3/3/2020 6:01:44 PM ACADIA Pharma, Neuren Pharma Announce RPD Designation For Trofinetide For Treatment Of Rett Syndrome
7/26/2012 7:45:11 AM Acadia Pharma: What's Next?
6/16/2008 2:33:36 PM Friedman Billings Ramsey Lowers ACADIA Pharmaceuticals Inc (ACAD) To Market Perform From Outperform With $8 Down From $21 Price Target